Patents Examined by Kristin A Vajda
  • Coumarin compounds and their uses as fluorescent labels
    Patent number: 11371078
    Abstract: The present application relates to new coumarin compounds and their uses as fluorescent labels. The compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: June 28, 2022
    Assignee: Illumina Cambridge Limited
    Inventor: Nikolai Nikolaevich Romanov
  • Antiviral agents for drug-resistant influenza A
    Patent number: 11365174
    Abstract: An effective therapeutic agent for the M2 channel comprising sulfonylamide or oxabicyclo structures effective for treating amantadine-resistant influenza A infections, and methods of treating amantadine-resistant influenza A infections through administration of the same.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: June 21, 2022
    Assignees: Thomas Jefferson University, Ramot At Tel-Aviv University LTD.
    Inventors: Nir Ben-Tal, Roger S. Armen, Laurence C. Eisenlohr, Jitendra Belani, Michael Miller, Inbar Fish, Ori Kalid
  • Compounds and methods for inhibiting CPY26 enzymes
    Patent number: 11364220
    Abstract: Compounds described herein are inhibitors of retinoic add inducible P450 (CYP26) enzymes, and are useful for treating diseases that are responsive to retinoids. Certain compounds have retinoid activity, are resistant to CYP26-mediated catabolism, and are used for treating diseases that are responsive to retinoids.
    Type: Grant
    Filed: November 26, 2020
    Date of Patent: June 21, 2022
    Assignee: Queen's University at Kingston
    Inventors: Donald Andrew Cameron, Martin Petkovich, Toni Kristian Rantanen, Victor Snieckus, Johnathan Board, Suneel Singh, Ashishkumar Jayantilal Maheta
  • Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
    Patent number: 11365198
    Abstract: The present disclosure relates to pharmaceutical compositions of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and corresponding methods of treating psoriatic arthritis.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: June 21, 2022
    Assignee: AbbVie Inc.
    Inventors: Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Aileen L. Pangan, Jaclyn Kay Anderson
  • Heterocyclic amides useful as protein modulators
    Patent number: 11365190
    Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: June 21, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Adam Kenneth Charnley, Gren Z. Wang, Joseph J. Romano
  • Means for treating cardiovascular disease
    Patent number: 11357825
    Abstract: A means for treating cardiovascular disease, in particular chronic heart failure, especially in terms of a more specific treatment preventing or minimizing pathological hypertrophic signaling while leaving cardiac contractility largely intact. For this purpose the present invention provides a means for treating cardiovascular disease, in particular chronic heart failure, the means specifically inhibiting or causing inhibition of components of the ?1-AR/cAMP pathway generating cAMP resulting from activation of the ?1-adrenoceptor on the cardiomyocyte cell crest.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: June 14, 2022
    Assignee: Universitaetsklinikum Hamburg-Eppendorf
    Inventors: Viacheslav Nikolaev, Alexander Froese
  • Cysteamine prodrugs
    Patent number: 11357750
    Abstract: Described herein are prodrugs of cysteamine and pharmaceutically acceptable salts, solvates, and esters thereof. Also described herein are pharmaceutical compositions comprising prodrugs of cysteamine, or pharmaceutically acceptable salts, solvates, and esters thereof, and methods of treatment comprising administering prodrugs of cysteamine, or pharmaceutically acceptable salts, solvates, and esters thereof.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: June 14, 2022
    Assignee: Children's Hospital Medical Center
    Inventor: Stephen Perrett
  • Production method for dicyanocyclohexane
    Patent number: 11352318
    Abstract: The present invention provides a production method for dicyanocyclohexane, including a step of obtaining dicyanocyclohexane by reacting cyclohexanedicarboxylic acid and/or a salt thereof, or a heated concentrate of an aqueous ammonia solution of cyclohexanedicarboxylic acid with ammonia in a solvent having a boiling point equal to or higher than a reaction temperature.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: June 7, 2022
    Assignee: Mitsubishi Gas Chemical Company, Inc.
    Inventors: Akifumi Iida, Emi Nakano, Yutaka Kanbara
  • Rosin-based small molecular weight hydrogelator and its application
    Patent number: 11352317
    Abstract: The present disclosure discloses a rosin-based small molecular weight hydrogelator and an application thereof, and belongs to the fields of supramolecular chemistry, surfactant science and chemical utilization of rosin. The rosin-based small molecular hydrogel of the present disclosure can gel water at a very low concentration, and the critical gelling concentration is only 0.176 wt %. On average, each gelling agent molecule can hold 13,889 water molecules, which exhibits extremely high gel efficiency and the formed small molecular hydrogel also exhibits extremely high stability. This small molecule hydrogel is derived from the natural product rosin and has a mild nature. It can be used in the fields of drug sustained-release, tissue engineering, daily chemicals, medicine and so on.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: June 7, 2022
    Assignee: Jiangnan University
    Inventors: Binglei Song, Tingting Yan, Danping Wang, Zhenggang Cui
  • Formation of N-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic ?-N-protected amino ester
    Patent number: 11345668
    Abstract: A method for the synthesis of N-protected 3,6-aminoalkyl-2,5-diketopiperazines is provided. The method includes obtaining a cyclic ?-N protected active amino ester and adding it to a mixture of an amine catalyst in an organic solvent.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: May 31, 2022
    Assignee: MANNKIND CORP.
    Inventors: John J. Freeman, Otto Phanstiel, William Elliot Bay, Kelly Sullivan Kraft
  • Process for the preparation of lifitegrast
    Patent number: 11345683
    Abstract: The present invention provides dibenzylamine salt of Lifitegrast (XV), and diphenylamine salt of Lifitegrast (XVI) and the use of the above salts in the purification process of Lifitegrast (I). The present invention relates to a process for the preparation of Lifitegrast (I).
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: May 31, 2022
    Assignee: Aurobindo Pharma Ltd
    Inventors: Praveen Kumar Neela, Guruswamy Batthini, Vijay Kumar Gupta Gangisetty, Ravikanth Dupud, Srikanth Sai Alur, Sivakumaran Meenakshisunderam
  • MAGL inhibitors
    Patent number: 11332453
    Abstract: Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: May 17, 2022
    Assignee: H. LUNDBECK A/S
    Inventors: Cheryl A. Grice, Daniel J. Buzard, Michael B. Shaghafi
  • Antimicrobial composition
    Patent number: 11331289
    Abstract: The present invention relates to a new topical composition comprising niclosamide and/or oxyclozanide and to the use of said composition for the treatment or prevention of pyoderma or dermatitis in non-human mammals.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: May 17, 2022
    Assignees: CEVA SANTE ANIMALE, UNION THERAPEUTICS A/S
    Inventors: Jérôme Guyonnet, Claudine Zemiriline, Pascal Butty
  • Ophthalmic composition containing clathrated antioxidant substance, and use thereof
    Patent number: 11331282
    Abstract: The present invention provides an ophthalmic composition and a use thereof. In one embodiment of the present invention, an ophthalmic composition containing a clathrated antioxidant substance is provided. In some of embodiments of the present invention, a composition for treating or preventing an ophthalmic disease, an ophthalmic disorder or an ophthalmic symptom is provided, wherein the ophthalmic disease, the ophthalmic disorder or the ophthalmic symptom includes, but is not limited to, dry eye or a dry eye-like ophthalmic disease, conjunctivitis, corneal ulcer, age-related macular degeneration, cataract, pseudoexfoliation syndrome, and symptoms in these diseases which can be ameliorated by increasing the quantity of tears and/or goblet cells and/or mucin.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: May 17, 2022
    Inventors: Junwen Qin, Yuji Takahashi, Shigeru Kakuta, Shigeru Kyuwa
  • Nanoemulsions and methods for cancer therapy
    Patent number: 11332494
    Abstract: An oxysterol or oxysterol-like compound is provided, which finds use in treating and/or targeting cancer.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: May 17, 2022
    Assignee: Fernando Thome Kreutz
    Inventor: Fernando Thome Kreutz
  • Methods and compositions for modulating splicing
    Patent number: 11326165
    Abstract: Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: May 10, 2022
    Assignee: SKYHAWK THERAPEUTICS, INC.
    Inventors: Michael Luzzio, Kathleen McCarthy, William Haney
  • Small molecule inducers of autophagy
    Patent number: 11325898
    Abstract: Small molecule disruptors of Beclin-1/Bcl-2 protein-protein interactions induce autophagy and hence are useful for treating a variety of indications where stimulation of autophagy is therapeutically useful, including cancer, infection immunity, neurodegeneration, longevity.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: May 10, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jef De Brabander, Qiren Liang, Beth Levine, Wei-Chung Chiang
  • IRAK degraders and uses thereof
    Patent number: 11318205
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: May 3, 2022
    Assignee: KYMERA THERAPEUTICS, INC.
    Inventors: Nello Mainolfi, Nan Ji, Arthur F. Fluge, Matthew M. Weiss, Yi Zhang
  • Pulmonary hypertension treatment
    Patent number: 11318331
    Abstract: Disclosed herein is a therapeutically active agent usable in the treatment of pulmonary arterial hypertension (PAH), for use in the treatment of pulmonary arterial hypertension, as well as methods of treating PAH, said treatment and methods comprising administering such an active agent and effecting pulmonary artery denervation in the subject. In some aspects, a sub-therapeutically effective amount of the active agent is administered. In some aspects, the method is devoid of administering such an active agent for at least one month subsequent to the denervation. Further disclosed is a method of treating PAH comprising determining a responsiveness of the subject to at least one therapeutically active agent usable in treating PAH; and effecting pulmonary artery denervation in a subject responsive to the active agent(s).
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: May 3, 2022
    Assignee: Sonivie Ltd.
    Inventors: Or Shabtay, Dalit Shav
  • Diorganylphosphinic acid salts, method for the production thereof and the use thereof
    Patent number: 11312910
    Abstract: The invention relates to diorganylphosphinic salts containing 0.0001% to 99.9999% by weight of iron, to a process for preparation thereof and to the use thereof.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: April 26, 2022
    Assignee: Clariant International Ltd
    Inventors: Harald Bauer, Sebastian Hörold, Martin Sicken